# Kabosu

[![License: MIT](https://img.shields.io/badge/License-MIT-yellow.svg)](LICENSE)
![Python](https://img.shields.io/badge/python-3.9%2B-blue)
![GitHub last commit](https://img.shields.io/github/last-commit/Aridoge13/Kabosu)

[![Logo](Kabosu/src/Untitled.png)]

---

**Kabosu** is an open‑source framework that integrates multi‑omics data (genomics, transcriptomics, proteomics, metabolomics) with deep learning to deliver interpretable predictions for disease risk, diagnosis, and personalized therapy. By combining polygenic risk scores (PRS) with pathway‑level analysis and in silico drug simulations, Kabosu aims to make precision medicine accessible, transparent, and computationally efficient, with a focus on running on the most modest hardware.


## Vision

Personalized medicine promises earlier diagnosis, tailored therapies, and better outcomes, yet its adoption is hindered by fragmented data sources, computational bottlenecks, and a lack of interpretable models. Kabosu is designed to bridge this gap by:

- **Integrating** diverse biological data into a unified, analyzable framework.
- **Predicting** disease susceptibility from individual and population‑level genetic variation.
- **Simulating** drug effects on patient‑specific molecular pathways before clinical use.
- **Empowering** researchers and clinicians with explainable AI and a user‑friendly interface.

## Key Features currently planned 
| Feature | Description |
|---------|-------------|
| **Multi‑Omics Integration** | Seamlessly combine genomics (WGS/WES), transcriptomics (RNA‑seq), proteomics, and metabolomics data for a holistic view of disease mechanisms. |
| **AI‑Driven Risk Prediction** | Use feed‑forward neural networks (FFNN) and gradient‑boosted decision trees (GBDT) to model disease susceptibility. PRS calculated via PLINK are incorporated as features, leveraging both statistical genetics and machine learning. |
| **Pathway‑Aware Diagnosis** | Map patient omics profiles onto biochemical pathways (KEGG, Reactome) to identify dysregulated modules and link them to disease phenotypes. |
| **In Silico Drug Testing** | Simulate drug‑target interactions on patient‑specific pathway models to predict efficacy and adverse effects, enabling therapy personalization. |
| **Explainable AI** | SHAP, LIME, and attention mechanisms provide interpretable outputs, building trust with clinicians and researchers. |
| **Efficiency‑First Design** | Optimized for time complexity and minimal hardware requirements through careful algorithm selection, parallelization, and use of state‑of‑the‑art open‑source libraries. |
| **Open & Extensible** | Fully open‑source, modular architecture invites community contributions. Easily plug in new data types, models, or visualization tools. |


## How It Works (Planned Development)

Kabosu treats PRS as one informative layer within a much broader integrative framework. The workflow consists of several modular stages:

1. **Data Ingestion & Preprocessing**  
   - Accepts raw or pre‑processed data: VCF (genotypes), FASTQ/expression matrices (transcriptomics), MS data (proteomics), etc.  
   - Quality control, normalization, and batch correction using standard bioinformatics tools.

2. **Feature Engineering**  
   - **Genomics**: Compute polygenic risk scores via PLINK (clumping + thresholding, or LDpred). Optionally include rare variants, structural variants.  
   - **Transcriptomics**: Differential expression, co‑expression networks, pathway enrichment scores.  
   - **Proteomics / Metabolomics**: Abundance profiles, pathway activity scores.  
   - All features are harmonized into a unified patient‑level matrix.

3. **Machine Learning Modeling**  
   - Train ensemble models (GBDT, Random Forest) or neural networks (FFNN) to predict disease risk, severity, or treatment response.  
   - Models can incorporate both omics‑derived features and clinical covariates.  
   - Cross‑validation and permutation tests ensure robust evaluation.

4. **Pathway & Network Analysis**  
   - Map features onto biological pathways (using tools like GSEA, Cytoscape).  
   - Identify key drivers and modules associated with the phenotype.

5. **Drug Simulation**  
   - Use deep learning‑based drug‑target interaction models (e.g., graph neural networks on molecular structures) to predict binding affinities.  
   - Simulate how candidate drugs modulate the patient’s dysregulated pathways.

6. **Interpretation & Visualization**  
   - Generate reports with feature importance, pathway enrichment, and drug recommendations.  
   - Web‑based dashboard for interactive exploration (React frontend, Flask backend).

---

## Technical Stack (subject to change)

| Component | Tools |
|---------|------|
| **Data Processing** | Python (pandas, numpy, scipy, Biopython, pysam), Snakemake/Nextflow |
| **Machine Learning** | TensorFlow, PyTorch, scikit‑learn, XGBoost, LightGBM, CatBoost |
| **Explainability** | SHAP, LIME, Captum |
| **Genetics Tools** | PLINK, bcftools, samtools, LDlink |
| **Pathway Analysis** | GSEA, Enrichr, Cytoscape, NetworkX, Pathway Commons |
| **Visualization** | matplotlib, seaborn, plotly, bokeh |
| **Web Framework** | React.js (frontend), Flask/Django (backend), PostgreSQL/MongoDB |
| **Cloud / HPC** | AWS/GCP/Azure, Docker, Kubernetes (optional) |

All components are open‑source and carefully selected to balance performance with accessibility.

Dependencies will evolve with project phases.

---


## Installation (Development)

Kabosu is under active development. A stable release will be available soon. For now, you can clone the repository and set up a development environment:

```bash
git clone https://github.com/Aridoge13/Kabosu
cd Kabosu

conda create -n kabosu python=3.9
conda activate kabosu

```

## Contributions

This is a research-driven project.

Contributions are welcome **if they align with the project philosophy**:
- reproducibility over novelty
- analysis over hype
- clarity over performance claims

Open an issue before major contributions.

## Acknowledgement

We thank the open‑source community and the developers of the countless libraries that make Kabosu possible. Special thanks to the contributors of TCGA, GTEx, PLINK, and the PyData ecosystem.

## License

MIT License: [LICENSE](License.md)

## Contact
- Email: aritra.mukherjee98@gmail.com
- Linkedin: www.linkedin.com/in/aritra-mukherjee-82b070125
- ORCID: https://orcid.org/0000-0002-6061-611X


Kabosu is powered by the message - Do Only Good Everyday. 